438 related articles for article (PubMed ID: 30231308)
21. Safety and efficacy of blinatumomab: a real world data.
Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
[TBL] [Abstract][Full Text] [Related]
22. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
Wynne J; Wright D; Stock W
Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
[TBL] [Abstract][Full Text] [Related]
23. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
Le Jeune C; Thomas X
Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
[TBL] [Abstract][Full Text] [Related]
24. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
26. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Queudeville M; Schlegel P; Heinz AT; Lenz T; Döring M; Holzer U; Hartmann U; Kreyenberg H; von Stackelberg A; Schrappe M; Zugmaier G; Feuchtinger T; Lang P; Handgretinger R; Ebinger M
Eur J Haematol; 2021 Apr; 106(4):473-483. PubMed ID: 33320384
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.
Ponvilawan B; Vittayawacharin P; Tunsing P; Owattanapanich W
Technol Cancer Res Treat; 2021; 20():15330338211037434. PubMed ID: 34350787
[TBL] [Abstract][Full Text] [Related]
28. How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?
Gökbuget N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):261-274. PubMed ID: 29050699
[TBL] [Abstract][Full Text] [Related]
29. Antibody-based therapies in patients with acute lymphoblastic leukemia.
Dinner S; Liedtke M
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):9-15. PubMed ID: 30504286
[TBL] [Abstract][Full Text] [Related]
30. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
Aldoss I; Forman SJ
Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
Maino E; Bonifacio M; Scattolin AM; Bassan R
Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
[TBL] [Abstract][Full Text] [Related]
32. Antibody based therapy in relapsed acute lymphoblastic leukemia.
Jammal N; Chew S; Jabbour E; Kantarjian H
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
[TBL] [Abstract][Full Text] [Related]
33. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
[TBL] [Abstract][Full Text] [Related]
34. Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia.
Elitzur S; Arad-Cohen N; Barzilai-Birenboim S; Ben-Harush M; Bielorai B; Elhasid R; Feuerstein T; Gilad G; Gural A; Kharit M; Litichever N; Nirel R; Weinreb S; Wolach O; Toren A; Izraeli S; Jacoby E
Pediatr Blood Cancer; 2019 Oct; 66(10):e27898. PubMed ID: 31264788
[TBL] [Abstract][Full Text] [Related]
35. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
[TBL] [Abstract][Full Text] [Related]
36. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
Thota S; Advani A
Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
[TBL] [Abstract][Full Text] [Related]
37. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Folan SA; Rexwinkle A; Autry J; Bryan JC
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
[TBL] [Abstract][Full Text] [Related]
38. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.
Kegyes D; Jitaru C; Ghiaur G; Ciurea S; Hoelzer D; Tomuleasa C; Gale RP
Blood Rev; 2023 May; 59():101042. PubMed ID: 36732205
[TBL] [Abstract][Full Text] [Related]
39. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
[TBL] [Abstract][Full Text] [Related]
40. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
